News
and updates
News
and updatesAdult dolutegravir could offer a practical and accessible treatment for children living with HIV
Adult doses of an antiviral drug could offer a practical and accessible option for children weighing 20-25kg living with HIV. The results of the pharmacokinetic sub-study (measuring levels of drug in the blood to check if doses are correct), part of the ODYSSEY trial, were presented at the Conference on Retroviruses and Opportunistic Infections, in Seattle, Washington.
ODYSSEY: recruitment has completed!
We are pleased to announce that recruitment to the main trial has now completed. We have recruited slightly more than the total target of 700 participants: 312 recruited into ODYSSEY A (naïve to HIV treatment) and 396 into ODYSSEY B (starting second line HIV treatment). A huge thank you to all involved in achieving this milestone!
Recruitment of children 3-<14kg has commenced at sites taking part in the pharmacokinetic substudy, and will continue until 60 children 3-<14kg have been recruited.
ODYSSEY B has completed recruitment with 395 children enrolled
ODYSSEY B, which compares dolutegravir versus standard-of-care drugs in HIV-infected children who are starting second-line treatment, has completed recruitment ahead of target. 395 children have enrolled, mostly in Africa. Enrollment into ODYSSEY A for children starting treatment for the first time continues.
A further step for the ODYSSEY trial
With more than 350 patients randomized into the trial, ODYSSEY has reached 50% of its recruitment target. Congratulations to the ODYSSEY team!
First patient enrolled in ODYSSEY study
We are happy to announce that the first patient was enrolled in the ODYSSEY study by the team in Zimbabwe. We encourage all the sites to follow.